NO20070453L - Kondenserte heterocykliske kinase inhibitorer - Google Patents
Kondenserte heterocykliske kinase inhibitorerInfo
- Publication number
- NO20070453L NO20070453L NO20070453A NO20070453A NO20070453L NO 20070453 L NO20070453 L NO 20070453L NO 20070453 A NO20070453 A NO 20070453A NO 20070453 A NO20070453 A NO 20070453A NO 20070453 L NO20070453 L NO 20070453L
- Authority
- NO
- Norway
- Prior art keywords
- kinase inhibitors
- condensed heterocyclic
- heterocyclic kinase
- useful
- protein kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58345904P | 2004-06-28 | 2004-06-28 | |
US61256304P | 2004-09-23 | 2004-09-23 | |
PCT/US2005/022682 WO2006004636A2 (en) | 2004-06-28 | 2005-06-28 | Fused heterocyclic kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20070453L true NO20070453L (no) | 2007-01-24 |
Family
ID=35457856
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20070453A NO20070453L (no) | 2004-06-28 | 2007-01-24 | Kondenserte heterocykliske kinase inhibitorer |
NO20070514A NO20070514L (no) | 2004-06-28 | 2007-01-26 | Pyrrolotriazin kinase inhibitorer |
NO20070506A NO20070506L (no) | 2004-06-28 | 2007-01-26 | Fremgangsmater og mellomprodukter nyttige for fremstilling av kondenserte heterocykliske kinase inhibitorer. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20070514A NO20070514L (no) | 2004-06-28 | 2007-01-26 | Pyrrolotriazin kinase inhibitorer |
NO20070506A NO20070506L (no) | 2004-06-28 | 2007-01-26 | Fremgangsmater og mellomprodukter nyttige for fremstilling av kondenserte heterocykliske kinase inhibitorer. |
Country Status (14)
Country | Link |
---|---|
US (2) | US7173031B2 (de) |
EP (3) | EP1768983A2 (de) |
JP (3) | JP4860609B2 (de) |
KR (3) | KR20070037448A (de) |
AR (2) | AR049536A1 (de) |
AU (2) | AU2005260056B2 (de) |
BR (1) | BRPI0512722A (de) |
CA (1) | CA2571680A1 (de) |
IL (1) | IL180325A0 (de) |
MX (2) | MXPA06015192A (de) |
NO (3) | NO20070453L (de) |
PE (2) | PE20060374A1 (de) |
TW (2) | TW200604184A (de) |
WO (3) | WO2006004884A2 (de) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7030112B2 (en) * | 2003-03-25 | 2006-04-18 | Bristol-Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
US9169406B2 (en) * | 2003-08-25 | 2015-10-27 | Dow Global Technologies Llc | Coating compositions |
AU2004275842B2 (en) * | 2003-09-26 | 2010-09-02 | Exelixis Inc. | c-MET modulators and methods of use |
DE10357510A1 (de) * | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroarylsubstituierte Benzole |
BRPI0507201A (pt) | 2004-02-27 | 2008-06-10 | Eisai R & D Man Company Ltd | derivado de piridina e derivado de pirimidina (1) |
EP2786995A1 (de) * | 2004-03-30 | 2014-10-08 | Vertex Pharmaceuticals Incorporated | Als Inhibitoren von JAK und anderen Proteinkinasen nützliche Azaindole |
DE102004017438A1 (de) * | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
TW200538453A (en) * | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US7432373B2 (en) * | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
JP5368701B2 (ja) * | 2004-07-02 | 2013-12-18 | エクセリクシス、インコーポレイテッド | c−Metモジュレーター及び使用方法 |
RU2007107167A (ru) * | 2004-07-30 | 2008-09-10 | Метилджин, Инк. (Ca) | Ингибиторы передачи сигнала рецептора vegf и рецептора hgf |
US7504521B2 (en) * | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
PE20060421A1 (es) | 2004-08-12 | 2006-06-01 | Bristol Myers Squibb Co | Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa |
US7569725B2 (en) * | 2004-10-21 | 2009-08-04 | Britsol-Myers Squibb Company | Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7151176B2 (en) * | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
US8875040B2 (en) * | 2005-06-07 | 2014-10-28 | Rockwell Automation Technologies, Inc. | Universal web-based reprogramming method and system |
TW200635927A (en) * | 2004-12-22 | 2006-10-16 | Bristol Myers Squibb Co | Synthetic process |
AU2006229343A1 (en) * | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency |
US7470693B2 (en) * | 2005-04-21 | 2008-12-30 | Bristol-Myers Squibb Company | Oxalamide derivatives as kinase inhibitors |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
EP1957498B1 (de) * | 2005-05-20 | 2017-02-15 | MethylGene Inc. | Vegf- und hgf-rezeptorensignalisierungshemmer |
DK1904504T3 (da) * | 2005-05-20 | 2014-06-23 | Methylgene Inc | Inhibitorer af vegf-receptor- og hgf-receptorsignalering |
US7402582B2 (en) * | 2005-07-01 | 2008-07-22 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
US7405213B2 (en) * | 2005-07-01 | 2008-07-29 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
US7232901B2 (en) | 2005-07-01 | 2007-06-19 | Bristol-Myers Squibb Company | Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates |
TW200745104A (en) * | 2005-08-05 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Multikinase inhibitor |
NZ566793A (en) | 2005-08-24 | 2010-03-26 | Eisai R&D Man Co Ltd | Novel pyridine derivative and pyrimidine derivative |
US7732613B2 (en) * | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
CA2635888A1 (en) * | 2006-01-04 | 2007-07-19 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US7723330B2 (en) * | 2006-03-07 | 2010-05-25 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
AR060061A1 (es) * | 2006-03-22 | 2008-05-21 | Methylgene Inc | Inhibidores de la actividad de la proteina tirosina quinasa |
PT2010538E (pt) * | 2006-04-21 | 2013-02-22 | Bristol Myers Squibb Co | Processo para a preparação de éster 2-[4-(4-fluoro-2- metil-1h-indol-5-iloxi)-5-metilpirrolo[2,1-f][1,2,4]- triazin-6-iloxi]-1 -metiletílico do ácido [(1r), 2s]-2- aminopropiónico |
TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
TW200808771A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
JP2009537632A (ja) * | 2006-05-19 | 2009-10-29 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 過剰増殖性障害および血管新生障害の処置に有用なピリドンカルボキサミド誘導体 |
CN101528702A (zh) * | 2006-06-08 | 2009-09-09 | 阿雷生物药品公司 | 喹啉化合物和使用方法 |
CN101541783B (zh) | 2006-06-30 | 2014-10-01 | 苏尼西斯制药有限公司 | 吡啶酮基pdk1抑制剂 |
EP2062886B1 (de) * | 2006-08-23 | 2011-11-30 | Eisai R&D Management Co., Ltd. | Salz eines phenoxypyridinderivats oder kristall davon und verfahren zu dessen herstellung |
US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
US20080255155A1 (en) * | 2006-10-18 | 2008-10-16 | Stephane Raeppel | Kinase inhibitors and uses thereof |
EP2079738A2 (de) * | 2006-10-27 | 2009-07-22 | Glaxo Group Limited | 7-azaindolderivate als c-met-kinaseinhibitoren |
JP5276005B2 (ja) * | 2006-11-08 | 2013-08-28 | ブリストル−マイヤーズ スクイブ カンパニー | ピリジノン化合物 |
WO2008116064A2 (en) * | 2007-03-21 | 2008-09-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
AU2008293038B2 (en) | 2007-08-29 | 2013-08-29 | Mirati Therapeutics, Inc. | Inhibitors of protein tyrosine kinase activity |
WO2009026720A1 (en) * | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
DE102007051762A1 (de) | 2007-10-30 | 2009-05-07 | Bayer Healthcare Ag | Substituierte Pyrrolotriazine und ihre Verwendung |
AR069206A1 (es) | 2007-11-06 | 2010-01-06 | Astrazeneca Ab | Derivados de 2-pirazinona, proceso para preparalos, composiciones farmaceuticas que los comprenden, proceso de preparacion de las mismas y usos en el tratamiento de trastornos osteoarticularesy del aparato respiratorio, entre otros. |
US8183225B2 (en) | 2007-11-08 | 2012-05-22 | New York University | Inhibition of bone resorption using medical implants containing adenosine receptor antagonists |
JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
ES2531396T3 (es) | 2008-01-23 | 2015-03-13 | Bristol Myers Squibb Co | Proceso para preparar compuestos de piridinona |
CN101977906B (zh) | 2008-01-23 | 2014-11-05 | 百时美施贵宝公司 | 4-吡啶酮化合物及其用于癌症的用途 |
MX2010009729A (es) * | 2008-03-05 | 2010-12-21 | Methylgene Inc | Inhibidores de actividad de proteina tirosina quinasa. |
JP2011513483A (ja) * | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン |
UY31982A (es) * | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
UY31984A (es) * | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. |
TWI365185B (en) | 2008-07-24 | 2012-06-01 | Lilly Co Eli | Amidophenoxyindazoles useful as inhibitors of c-met |
KR100961410B1 (ko) * | 2008-10-14 | 2010-06-09 | (주)네오팜 | 단백질 키나제 억제제로서 헤테로사이클릭 화합물 |
AR074830A1 (es) | 2008-12-19 | 2011-02-16 | Cephalon Inc | Pirrolotriazinas como inhibidores de alk y jak2 |
KR102187034B1 (ko) | 2009-01-16 | 2020-12-04 | 엑셀리시스, 인코포레이티드 | 암 치료용 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
TW201036957A (en) * | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
US20120136033A1 (en) * | 2009-05-18 | 2012-05-31 | President And Fellows Of Harvard College | Small Molecule Antagonists of Phosphatidylinositol-3,4,5-Triphosphate (PIP3) and Uses Thereof |
HUE031048T2 (en) | 2009-06-17 | 2017-06-28 | Vertex Pharma | Influenza virus replication inhibitors |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
KR20120089459A (ko) | 2009-08-24 | 2012-08-10 | 에즈셉피온 파마슈티컬즈, 인코포레이티드 | 키나제 저해제로서 5,6-바이사이클릭 헤테로아릴-함유 우레아 화합물 |
CA2800998A1 (en) | 2010-04-29 | 2011-11-10 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
NZ604306A (en) | 2010-05-17 | 2015-02-27 | Incozen Therapeutics Pvt Ltd | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
RU2560683C2 (ru) | 2010-06-25 | 2015-08-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации |
EP2423208A1 (de) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmazeutisch aktive Zusammensetzungen als Axl-Hemmer |
UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
CA2844588A1 (en) * | 2011-08-10 | 2013-02-14 | Merck Patent Gmbh | Pyrido-pyrimidine derivatives |
CN107082779A (zh) | 2012-03-30 | 2017-08-22 | 理森制药股份公司 | 作为c‑met 蛋白激酶调节剂的新化合物 |
TWI520962B (zh) * | 2012-06-29 | 2016-02-11 | As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives | |
CN104755463A (zh) | 2012-12-21 | 2015-07-01 | 卫材R&D管理有限公司 | 非晶态形式的喹啉衍生物及其生产方法 |
EP2948454B1 (de) * | 2013-01-24 | 2017-05-31 | Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) | Triazinverbindungen und verfahren zur herstellung davon |
US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
RS57542B1 (sr) * | 2013-10-17 | 2018-10-31 | Blueprint Medicines Corp | Kompozicije korisne za lečenje poremećaja povezanih sa kit-om |
CA2930103A1 (en) | 2013-11-13 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
CN105849105B (zh) | 2013-11-13 | 2018-02-13 | 沃泰克斯药物股份有限公司 | 制备流感病毒复制抑制剂的方法 |
PT3087070T (pt) * | 2013-12-26 | 2018-01-30 | Ignyta Inc | Derivados de pirazolo[1,5-a]piridina e métodos da sua utilização |
US9580416B2 (en) | 2014-07-02 | 2017-02-28 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
EP4089076A1 (de) | 2014-08-28 | 2022-11-16 | Eisai R&D Management Co., Ltd. | Hochreines chinolinderivat und verfahren zum herstellen davon |
CA2976325C (en) | 2015-02-25 | 2023-07-04 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
WO2016161952A1 (zh) | 2015-04-07 | 2016-10-13 | 广东众生药业股份有限公司 | 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物 |
EP3294735B8 (de) | 2015-05-13 | 2022-01-05 | Vertex Pharmaceuticals Incorporated | Hemmer der influenzavirenreplikation |
WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
KR20180018695A (ko) | 2015-06-16 | 2018-02-21 | 가부시키가이샤 프리즘 파마 | 항암제 |
WO2018059534A1 (zh) * | 2016-09-30 | 2018-04-05 | 广东众生药业股份有限公司 | 酪氨酸激酶抑制剂的晶型、盐型以及制备方法 |
EP3556761B1 (de) * | 2017-02-08 | 2021-03-03 | The National Institutes Of Pharmaceutical Research | Pyrrolo-aromatische heterocyclische verbindung, herstellungsverfahren dafür und medizinische verwendung davon |
US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
CA3079060A1 (en) * | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases |
EP3655406A1 (de) | 2017-07-18 | 2020-05-27 | Bayer Pharma Aktiengesellschaft | Substituierte pyrrolopyridinderivate |
TW202136268A (zh) * | 2018-07-13 | 2021-10-01 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
UY38349A (es) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
TW202039481A (zh) | 2018-12-21 | 2020-11-01 | 美商西建公司 | Ripk2之噻吩并吡啶抑制劑 |
MX2021012469A (es) | 2019-04-12 | 2022-01-18 | Blueprint Medicines Corp | Composiciones y metodos para el tratamiento de enfermedades mediadas por kit y pdgfra. |
EP3856341B1 (de) | 2019-04-12 | 2023-09-06 | Blueprint Medicines Corporation | Kristalline formen von s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amin und verfahren zur herstellung davon |
CN110407839B (zh) * | 2019-07-01 | 2022-01-04 | 江西科技师范大学 | 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用 |
JPWO2021020362A1 (de) | 2019-07-29 | 2021-02-04 | ||
TW202140426A (zh) * | 2020-02-14 | 2021-11-01 | 日商大鵬藥品工業股份有限公司 | 醯基硫脲化合物的製造方法 |
CN113880845A (zh) * | 2021-10-13 | 2022-01-04 | 广州六顺生物科技股份有限公司 | 吡咯并三嗪衍生物及其制备方法和应用 |
WO2023111996A1 (en) * | 2021-12-17 | 2023-06-22 | Reglagene Holding, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3646202A (en) | 1967-11-22 | 1972-02-29 | Merck & Co Inc | Liver fluke compositions containing salicylic acid derivatives |
JPS54115384A (en) | 1978-02-28 | 1979-09-07 | Hokko Chem Ind Co Ltd | Ryrazolyl pyrimidine derivative, and agricultural and horticultural fungicides |
CH648611A5 (de) | 1980-08-18 | 1985-03-29 | Staeubli Ag | Verfahren und schaftmaschine zur gleichstellung aller schaefte einer webmaschine. |
GB2106500B (en) | 1981-09-18 | 1986-01-02 | Dow Chemical Co | Method for making benzoylphenylureas |
DE3139457A1 (de) | 1981-10-03 | 1983-04-21 | Bayer Ag, 5090 Leverkusen | Neue substituierte benzanilidether, verfahren zu ihrer herstellung, ihre verwendung als fungizide und zwischenprodukte hierfuer |
DE3464368D1 (de) | 1983-03-09 | 1987-07-30 | Beecham Group Plc | Anti-inflammatory pyrazolo pyridines |
EP0151962A3 (de) | 1984-01-25 | 1985-10-02 | Beecham Group Plc | Pyrazolopyridin-Derivate |
US4663341A (en) | 1984-02-16 | 1987-05-05 | Rohm And Haas Company | Insecticidal n-aryl-3-aryl-4,5-dihydro-1h-pyrazole-1-carboxamides |
GB8404584D0 (en) | 1984-02-22 | 1984-03-28 | Beecham Group Plc | Compounds |
CH657015A5 (de) | 1984-06-27 | 1986-08-15 | Ciba Geigy Ag | Motten- und kaeferschutzmittel. |
JPS6133176A (ja) | 1984-07-24 | 1986-02-17 | Ishihara Sangyo Kaisha Ltd | N−ニトロベンゾイル−n’−ピリダジニルオキシフエニルウレア系化合物、それらの製造方法及びそれらを含有する抗癌剤 |
US4753940A (en) * | 1985-02-15 | 1988-06-28 | Ciba-Geigy Corporation | Barbituric acid derivatives |
JPS62135463A (ja) | 1985-12-09 | 1987-06-18 | Ishihara Sangyo Kaisha Ltd | N−ベンゾイルウレア系化合物、それらを含有する抗癌剤並びにそれらの製造方法 |
JPS625960A (ja) | 1986-03-05 | 1987-01-12 | Ishihara Sangyo Kaisha Ltd | ベンゾイルウレア系化合物の製造方法 |
JPS625959A (ja) | 1986-03-05 | 1987-01-12 | Ishihara Sangyo Kaisha Ltd | ベンゾイルウレア系化合物 |
JPS6262A (ja) | 1986-03-05 | 1987-01-06 | Ishihara Sangyo Kaisha Ltd | ベンゾイルウレア系化合物の製造方法 |
US4908056A (en) | 1986-04-25 | 1990-03-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
DE3830054A1 (de) | 1988-09-03 | 1990-03-15 | Boehringer Mannheim Gmbh | Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
US5132315A (en) * | 1989-05-19 | 1992-07-21 | The United States Of America As Represented By The Department Of Health And Human Services | Therapeutic application of an anti-invasive compound |
EP0420804A3 (en) | 1989-09-26 | 1991-11-27 | Ciba-Geigy Ag | Anthelmintic compounds |
SU1761753A1 (ru) | 1990-07-16 | 1992-09-15 | Ф. С. Михайлицын и Н. С. Уварова | 5-(2-Хлор-4-нитро(амино)фенокси) бензо-2,1,3-тиадиазол в качестве промежуточного соединени в синтезе 5- @ 2-хлор-4-[(2-окси-3,5-дибромбензоил)амино]фенокси @ бензо-2,1,3-тиадиазола, про вл ющего активность при гименолепидозе белых мышей |
US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
EP0874846B1 (de) * | 1995-11-01 | 2003-04-02 | Novartis AG | Purinderivate und verfahren zu ihrer herstellung |
JP4009681B2 (ja) * | 1995-11-07 | 2007-11-21 | キリンファーマ株式会社 | 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物 |
DE19710609A1 (de) | 1997-03-14 | 1998-09-17 | Bayer Ag | Substituierte Aminosalicylsäureamide |
SK179899A3 (en) | 1997-07-03 | 2001-12-03 | Du Pont Pharm Co | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
EA005889B1 (ru) * | 1997-11-11 | 2005-06-30 | Пфайзер Продактс Инк. | Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов |
TW515786B (en) | 1997-11-25 | 2003-01-01 | Nihon Nohyaku Co Ltd | Phthalic acid diamide derivatives, agricultural and horticultural insecticides, and a method for application of the insecticides |
US6362369B2 (en) | 1997-11-25 | 2002-03-26 | Nihon Nohyaku Co., Ltd. | Phthalic acid diamide derivatives fluorine-containing aniline compounds as starting material, agricultural and horticultural insecticides, and a method for application of the insecticides |
JP4253126B2 (ja) | 1998-01-29 | 2009-04-08 | アムジェン インコーポレイテッド | Ppar−ガンマ調節剤 |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
CZ299375B6 (cs) | 1998-11-30 | 2008-07-09 | Nihon Nohyaku Co., Ltd. | Ftalamidové deriváty nebo jejich soli, zemedelsko-zahradnický insekticid je obsahující a jeho použití |
US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
CA2361057C (en) | 1999-01-22 | 2010-04-06 | Kazuo Kubo | Quinoline derivatives and quinazoline derivatives |
HUP0200076A3 (en) | 1999-02-22 | 2003-01-28 | Bristol Myers Squibb Co | C-21 modified epothilones, process for their preparation, pharmaceutical compositions containing them |
GB9904103D0 (en) | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
GB9906566D0 (en) * | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
PL204437B1 (pl) | 1999-05-21 | 2010-01-29 | Bristol Myers Squibb Co | Pochodna pirolotriazyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie |
US6982265B1 (en) * | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
DK1516874T3 (en) | 1999-07-20 | 2015-11-23 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and compositions, processes for their use and preparation thereof |
US6355660B1 (en) | 1999-07-20 | 2002-03-12 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
CA2384291A1 (en) | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
BR0014139B1 (pt) | 1999-09-24 | 2011-09-20 | derivado de diamida aromática ou um seu sal, composição agrìcola e hortìcola, e, método para utilizar uma composição agrìcola e hortìcola. | |
AU2576501A (en) | 1999-12-08 | 2001-06-18 | Advanced Medicine, Inc. | Protein kinase inhibitors |
AU2223201A (en) | 1999-12-24 | 2001-07-09 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives and drugs containing the same |
US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
EP1149583A3 (de) | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Kombinationen bestehend aus Antagonisten des Corticotropin freisetzenden Faktors und Stoffen, die die Wachstumshormonsekretion fördern |
WO2001094353A1 (en) | 2000-06-06 | 2001-12-13 | Pfizer Products Inc. | Thiophene derivatives useful as anticancer agents |
FR2812633A1 (fr) | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
MX242553B (es) * | 2000-10-20 | 2006-12-06 | Eisai Co Ltd | Derivados aromaticos que contienen nitrogeno. |
ES2259051T3 (es) | 2000-11-17 | 2006-09-16 | Bristol-Myers Squibb Company | Procedimientos para el tratamiento de dolencias asociadas a la quinasa p38 y compuestos de pirrolotriacina utiles como inhibidores de quinasa. |
US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
AU2002232439A1 (en) | 2000-11-29 | 2002-06-11 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
WO2002051397A1 (fr) | 2000-12-22 | 2002-07-04 | Ishihara Sangyo Kaisha, Ltd. | Derives d'aniline ou sels de ceux-ci, ainsi qu'inhibiteurs de production de cytokine contenant ces derives |
WO2002072578A2 (en) * | 2001-03-08 | 2002-09-19 | Millennium Pharmaceuticals | (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases |
US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
WO2003000194A2 (en) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
CN100415720C (zh) | 2001-06-22 | 2008-09-03 | 麒麟医药株式会社 | 喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物 |
SE0102384D0 (sv) * | 2001-07-03 | 2001-07-03 | Pharmacia Ab | New compounds |
WO2003011028A1 (en) | 2001-08-01 | 2003-02-13 | Nissan Chemical Industries, Ltd. | Substituted amides and pest controllers |
EP1447405A4 (de) | 2001-10-17 | 2005-01-12 | Kirin Brewery | Chinolin- oder chinazolinderivate, die die autophosphorylierung von rezeptoren für den fibroblastenwachstumsfaktor hemmen |
TW200300350A (en) | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
JP2005510564A (ja) * | 2001-11-28 | 2005-04-21 | 藤沢薬品工業株式会社 | アポリポタンパク質b阻害剤としての複素環式アミド化合物 |
EP1769795B1 (de) | 2001-12-03 | 2013-07-24 | Bayer HealthCare LLC | Arylharnstoffverbindungen in Kombination mit anderen zytostatischen oder zytotoxischen Substanzen zur Behandlung von Krebs beim Menschen |
JP2003321472A (ja) | 2002-02-26 | 2003-11-11 | Takeda Chem Ind Ltd | Grk阻害剤 |
US6900208B2 (en) | 2002-03-28 | 2005-05-31 | Bristol Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
AU2003231034B2 (en) * | 2002-04-23 | 2009-03-05 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
TW200306841A (en) | 2002-04-23 | 2003-12-01 | Bristol Myers Squibb Co | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
US7388009B2 (en) * | 2002-04-23 | 2008-06-17 | Bristol-Myers Squibb Company | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
TWI272271B (en) * | 2002-07-19 | 2007-02-01 | Bristol Myers Squibb Co | Process for preparing certain pyrrolotriazine compounds |
EP1543009A4 (de) | 2002-08-02 | 2007-08-08 | Bristol Myers Squibb Co | Pyrrolotriazin-kinaseinhibitoren |
CA2515218A1 (en) | 2003-02-05 | 2004-08-26 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine kinase inhibitors |
US7030112B2 (en) * | 2003-03-25 | 2006-04-18 | Bristol-Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
DE10357510A1 (de) * | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroarylsubstituierte Benzole |
MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
WO2005121125A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
US7102002B2 (en) | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
TW200600513A (en) | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
US7504521B2 (en) | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
-
2005
- 2005-06-24 US US11/167,049 patent/US7173031B2/en active Active
- 2005-06-24 US US11/167,043 patent/US20050288290A1/en not_active Abandoned
- 2005-06-27 TW TW094121497A patent/TW200604184A/zh unknown
- 2005-06-27 TW TW094121488A patent/TW200607505A/zh unknown
- 2005-06-28 JP JP2007519322A patent/JP4860609B2/ja not_active Expired - Fee Related
- 2005-06-28 WO PCT/US2005/023198 patent/WO2006004884A2/en active Application Filing
- 2005-06-28 JP JP2007519390A patent/JP4782117B2/ja not_active Expired - Fee Related
- 2005-06-28 EP EP05764291A patent/EP1768983A2/de not_active Withdrawn
- 2005-06-28 CA CA002571680A patent/CA2571680A1/en not_active Abandoned
- 2005-06-28 KR KR1020067027370A patent/KR20070037448A/ko not_active Application Discontinuation
- 2005-06-28 MX MXPA06015192A patent/MXPA06015192A/es active IP Right Grant
- 2005-06-28 KR KR1020067026897A patent/KR20070026621A/ko not_active Application Discontinuation
- 2005-06-28 EP EP05791275A patent/EP1761268A4/de not_active Withdrawn
- 2005-06-28 PE PE2005000752A patent/PE20060374A1/es not_active Application Discontinuation
- 2005-06-28 WO PCT/US2005/023099 patent/WO2006004833A2/en active Application Filing
- 2005-06-28 AU AU2005260056A patent/AU2005260056B2/en not_active Ceased
- 2005-06-28 JP JP2007519416A patent/JP2008504368A/ja not_active Withdrawn
- 2005-06-28 MX MXPA06015032A patent/MXPA06015032A/es not_active Application Discontinuation
- 2005-06-28 BR BRPI0512722-0A patent/BRPI0512722A/pt not_active Application Discontinuation
- 2005-06-28 WO PCT/US2005/022682 patent/WO2006004636A2/en active Application Filing
- 2005-06-28 AR ARP050102668A patent/AR049536A1/es not_active Application Discontinuation
- 2005-06-28 PE PE2005000754A patent/PE20060524A1/es not_active Application Discontinuation
- 2005-06-28 KR KR1020067027376A patent/KR20070028458A/ko not_active Application Discontinuation
- 2005-06-28 AU AU2005259894A patent/AU2005259894C1/en not_active Ceased
- 2005-06-28 AR ARP050102669A patent/AR050254A1/es not_active Application Discontinuation
- 2005-06-28 EP EP05790229A patent/EP1771177A4/de not_active Withdrawn
-
2006
- 2006-12-25 IL IL180325A patent/IL180325A0/en unknown
-
2007
- 2007-01-24 NO NO20070453A patent/NO20070453L/no not_active Application Discontinuation
- 2007-01-26 NO NO20070514A patent/NO20070514L/no not_active Application Discontinuation
- 2007-01-26 NO NO20070506A patent/NO20070506L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20070453L (no) | Kondenserte heterocykliske kinase inhibitorer | |
ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
LTPA2016016I1 (lt) | Azetinidai kaip mek inhibitoriai, skirti proliferacinių ligų gydymui | |
EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
CY1114925T1 (el) | Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης | |
DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
DE60332604D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
NO20055496L (no) | Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer | |
DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
ATE493401T1 (de) | Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen | |
NO20071320L (no) | Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer. | |
NO20082508L (no) | Aminopyrimidiner anvendelige som kinaseinhibitorer | |
DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
DE60333387D1 (de) | Triazolopyridazine als proteinkinase-inhibitoren | |
EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
BRPI0606313A2 (pt) | derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia | |
NO20085217L (no) | Effektive pyrimidinderivater i behandlingen av kreft | |
NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
ATE493418T1 (de) | Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren | |
MX2007004248A (es) | Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |